Business Description
Jiangsu Kanion Pharmaceutical Co Ltd
NAICS : 325412
No. 58 Haichang South Road, Xinpu District, Jiangsu, Lianyungang, CHN, 222001
Compare
Compare
Traded in other countries / regions
600557.China
Description
Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.75 | |||||
| Interest Coverage | 60.28 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 5.79 | |||||
| Beneish M-Score | -3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.5 | |||||
| 3-Year EBITDA Growth Rate | -7.4 | |||||
| 3-Year EPS without NRI Growth Rate | -7.2 | |||||
| 3-Year FCF Growth Rate | 31.2 | |||||
| 3-Year Book Growth Rate | 4.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.39 | |||||
| 9-Day RSI | 45.31 | |||||
| 14-Day RSI | 46.98 | |||||
| 6-1 Month Momentum % | 44.32 | |||||
| 12-1 Month Momentum % | 46.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 2.15 | |||||
| Cash Ratio | 0.96 | |||||
| Days Inventory | 103.77 | |||||
| Days Sales Outstanding | 74.92 | |||||
| Days Payable | 102.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | -100 | |||||
| 3-Year Average Share Buyback Ratio | 1.3 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.16 | |||||
| Operating Margin % | 9.83 | |||||
| Net Margin % | 9.36 | |||||
| ROE % | 8.61 | |||||
| ROA % | 6.29 | |||||
| ROIC % | 10 | |||||
| ROC (Joel Greenblatt) % | 12.52 | |||||
| ROCE % | 8.59 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.17 | |||||
| PE Ratio without NRI | 22.17 | |||||
| Shiller PE Ratio | 21.87 | |||||
| Price-to-Owner-Earnings | 51.09 | |||||
| PS Ratio | 2.06 | |||||
| PB Ratio | 1.82 | |||||
| Price-to-Tangible-Book | 2.06 | |||||
| Price-to-Free-Cash-Flow | 11.52 | |||||
| Price-to-Operating-Cash-Flow | 9.47 | |||||
| EV-to-EBIT | 18.78 | |||||
| EV-to-EBITDA | 18.78 | |||||
| EV-to-Revenue | 1.85 | |||||
| EV-to-FCF | 10.19 | |||||
| Price-to-Projected-FCF | 1.1 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Graham-Number | 1.43 | |||||
| Price-to-Net-Current-Asset-Value | 5.82 | |||||
| Earnings Yield (Greenblatt) % | 5.33 | |||||
| Forward Rate of Return (Yacktman) % | -2.91 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,976.631 | ||
| EPS (TTM) (¥) | 0.65 | ||
| Beta | 0.48 | ||
| Volatility % | 36.75 | ||
| 14-Day RSI | 46.98 | ||
| 14-Day ATR (¥) | 0.635421 | ||
| 20-Day SMA (¥) | 14.451 | ||
| 12-1 Month Momentum % | 46.9 | ||
| 52-Week Range (¥) | 9.22 - 17.5 | ||
| Shares Outstanding (Mil) | 576.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jiangsu Kanion Pharmaceutical Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||